Provided by Tiger Fintech (Singapore) Pte. Ltd.

Seres Therapeutics

11.87
+1.019.30%
Post-market: 11.870.00000.00%16:52 EDT
Volume:107.17K
Turnover:1.23M
Market Cap:103.65M
PE:1.32
High:12.18
Open:11.00
Low:10.69
Close:10.86
Loading ...

Why China's Auto, Tech Giants Threaten Tesla’s Self-Driving Future

Reuters
·
10 Jun

Matthew R. Henn, Officer, Reports Disposal of Common Shares of Seres Therapeutics Inc

Reuters
·
20 May

Seres Therapeutics Shares Fall After Downgrade From Chardan

MT Newswires Live
·
09 May

Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25

MT Newswires Live
·
08 May

Seres Therapeutics Cut to Neutral From Buy by Chardan Capital

Dow Jones
·
08 May

Seres Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

BRIEF-Seres Therapeutics Inc Qtrly EPS $3.76

Reuters
·
07 May

Seres Therapeutics Inc Q1 Shr View $-0.54 -- Lseg Ibes Data

THOMSON REUTERS
·
07 May

Seres Therapeutics Q1 EPS $3.75 Beats $0.12 Estimate

Benzinga
·
07 May

Seres Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
05 May

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

GlobeNewswire
·
29 Apr

Seres Therapeutics trading resumes

TIPRANKS
·
23 Apr

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround

Zacks
·
17 Apr

Seres Therapeutics Approves Reverse Stock Split Plan

TIPRANKS
·
15 Apr

Seres Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
21 Mar

Seres Therapeutics Is Maintained at Sell by Goldman Sachs

Dow Jones
·
15 Mar

Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic?

Simply Wall St.
·
14 Mar

Q4 2024 Seres Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
14 Mar

Seres Therapeutics Advances SER-155 Program with FDA Support

TIPRANKS
·
14 Mar

Seres Therapeutics: Strategic Developments and Promising Clinical Data Justify Buy Rating

TIPRANKS
·
14 Mar